Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study helped address some of the controversies regarding the relationship of serum CETP mass to atherosclerosis, in addition to the association of ACS occurrence with circulating CETP levels.
|
31504738 |
2020 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Disruption of circadian rhythm by alternating light-dark cycles aggravates atherosclerosis development in APOE*3-Leiden.CETP mice.
|
31599473 |
2020 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the outcomes from clinical trials on many promising pharmaceutical agents against atherosclerosis (e.g., low-dose methotrexate, inhibitors against cholesteryl ester transfer protein) have been disappointing.
|
31697015 |
2020 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Molecular modeling and rational design of hydrocarbon-stapled/halogenated helical peptides targeting CETP self-binding site: Therapeutic implication for atherosclerosis.
|
31586754 |
2020 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the effect of such lipid-lowering interventions on atherosclerosis in APOE*3-Leiden.CETP mice, a well-established model for hyperlipidemia.
|
31843957 |
2020 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus far, it is unclear to what extent CETP is causally related to measures of atherosclerosis.
|
29174438 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The randomized placebo-controlled REVEAL trial demonstrated the clinical efficacy of the CETP inhibitor anacetrapib among patients with pre-existing atherosclerotic vascular disease.
|
31331193 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic OSM administration in APOE*3Leiden.CETP mice reduced atherosclerosis development.
|
31461490 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PCSK9 inhibition decreased total cholesterol in serum of APOE*3Leiden.CETP mice and prevented the development of atherosclerosis.
|
31366894 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Disease duration, which reflects accumulated metabolic abnormalities, may have blunted the potential effect of CETP on atherosclerosis.
|
30980187 |
2019 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because lack of cholesteryl ester transfer protein (CETP) is a major difference between murine and humans in lipoprotein metabolism, we aimed to create a novel Syrian Golden hamster model deficient in LCAT activity, which expresses endogenous CETP, to explore its metabolic features and particularly the influence of LCAT on the development of atherosclerosis.
|
29526535 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, CETP inhibitors have attracted considerable interest in atherosclerosis-related disease.
|
29424255 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, inulin did not reduce hypercholesterolemia or atherosclerosis development in E3L.CETP mice despite showing clear prebiotic activity, but resulted in manifestations of hepatic inflammation when combined with a high percentage of dietary cholesterol.
|
30409998 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the presence of CETP, AET positively influences gene expression in the arterial wall and macrophages of CETP-tg mice contributing to the RCT and prevention of atherosclerosis.
|
29867549 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously reported that patients with cholesteryl ester transfer protein (CETP) deficiency (CETP-D) have a higher prevalence of atherosclerotic cardiovascular disease, in spite of increased HDL-C levels.
|
29304079 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein).
|
29674325 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the ILLUMINATE Trial, treatment with the cholesteryl ester transfer protein inhibitor torcetrapib resulted in a significant increase in both atherosclerotic cardiovascular disease events and total mortality which was not explained by changes in the routinely measured plasma lipids.
|
28431663 |
2017 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we report a reduction in atherosclerosis in response to pharmacological stimulation of thermogenesis linked to increased HDL levels in APOE*3-Leiden.CETP mice.
|
28422089 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cholesteryl Ester Transfer Protein (CETP) is an important therapeutic target for the treatment of atherosclerotic cardiovascular disease.
|
27750148 |
2017 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results provide evidence that genetic ablation of CETP activity protects against cholesterol diet-induced atherosclerosis in rabbits.
|
28428219 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
As pigs are a good model for both lipid and AS research, we investigated the lipid metabolism of human CETP (hCETP) transgenic pigs and explored the mechanism of CETP in lipid modulation.
|
28893253 |
2017 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
|
28637178 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunotherapy is a feasible approach to treat atherosclerosis and given that genetically engineered plants are attractive hosts for vaccine development; we previously proved that the plant cell is able to synthesize a chimeric protein called CTB:p210:CETPe, which is composed of the cholera toxin B subunit (CTB) as immunogenic carrier and target epitopes from the cholesteryl ester transfer protein (CETP<sub>461-476</sub>) and apolipoprotein B100 (p210).
|
28965203 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CETP inhibitors have been widely studied as a pharmacologic therapy to target plasma cholesterol in order to reduce the risk of atherosclerotic cardiovascular disease .
|
27512081 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data revealed that human CETP may play an important role in the development of atherosclerosis mainly by decreasing HDL-C levels and increasing the accumulation of macrophage-derived foam cells.
|
29317793 |
2017 |